Cytoreductive Surgery combined with Hyperthermic Intraperitoneal Chemotherapy (CRS + HIPEC) is a complex, specialised surgical procedure that offers the only chance of cure for cancers that have spread to the peritoneal lining — a site previously considered untreatable with curative intent.
CRS + HIPEC is a two-component surgical procedure. The first part — Cytoreductive Surgery (CRS) — involves systematic surgical removal of all visible cancer deposits from the peritoneal surface (the lining of the abdominal and pelvic cavity). This may involve removing parts of the bowel, stomach, spleen, gallbladder, uterus, ovaries, and the peritoneal lining itself (peritonectomy).
The second part — HIPEC (Hyperthermic Intraperitoneal Chemotherapy) — is performed immediately after surgical debulking, while the patient is still on the operating table. Heated chemotherapy solution (at 41–43°C) is circulated through the abdominal cavity for 60–90 minutes, bathing the entire peritoneal surface in cytotoxic drug. Heat enhances drug penetration by up to 40 times compared to systemic IV chemotherapy.
Together, CRS removes the bulk of visible tumour and HIPEC eliminates the microscopic residual cancer cells — giving the patient the best possible chance of cure or long-term disease control. This procedure was previously unavailable for most peritoneal cancers, which were considered incurable. In expert hands, it has transformed the prognosis for selected patients.
HIPEC is one of the most demanding procedures in surgical oncology — in terms of technique, patient selection, and peri-operative management. When I tell a patient with peritoneal colorectal cancer that there is a chance of cure, it means everything to them. That is why every detail of this procedure — the PCI assessment, the completeness of cytoreduction, the drug and temperature choice — must be precisely right.
Patient selection is the single most important factor in outcome. An operation that achieves CC0 or CC1 cytoreduction in a patient with PCI ≤ 15 can deliver years of survival. The same operation in a patient with PCI 30 causes harm without benefit. My job is to make that distinction accurately.
— Dr. Vinod T. Gore, MBBS MS FAIS FIAGES FARIS (Edin)CRS + HIPEC is a single prolonged operation performed under general anaesthesia — combining radical surgical debulking with intraoperative chemotherapy perfusion.
Full laparotomy — all 13 abdominal regions systematically examined. Peritoneal Cancer Index (PCI 0–39) calculated intraoperatively. Decision made whether to proceed.
Systematic stripping of tumour-bearing peritoneum — parietal, pelvic, diaphragmatic, and visceral surfaces stripped of all visible disease.
Bowel resections, oophorectomy, splenectomy, cholecystectomy, or gastrectomy as required to achieve complete (CC0/CC1) cytoreduction. Anastomoses deferred.
Heated chemotherapy (41–43°C) circulated through the abdomen via inflow/outflow catheters for 60–90 minutes — targeting all residual microscopic disease.
HIPEC — The Critical StepBowel continuity restored with anastomoses. Abdomen closed. Patient transferred to ICU for monitoring. Total operative time 6–12 hours.
At normal body temperature, chemotherapy drugs penetrate only a few cell layers into tumour tissue when applied topically. Heat dramatically changes this. At 41–43°C, cancer cell membranes become more permeable, drug uptake increases by up to 40-fold, and heat itself is directly cytotoxic to cancer cells (which are more heat-sensitive than normal cells).
The peritoneal route also creates a "plasma-peritoneal barrier" — drug concentrations in the peritoneal cavity can be 25 times higher than in the blood. This means the tumour receives a far higher drug dose than would ever be safely achievable by IV chemotherapy — without causing the systemic toxicity of high-dose IV treatment.
The combination of mechanical tumour removal (CRS) followed immediately by high-concentration heated chemotherapy bathing the entire peritoneal surface is uniquely effective — and cannot be replicated by any systemic or regional treatment alone.
CRS + HIPEC is indicated for peritoneal surface malignancies — cancers that have spread to or originated from the lining of the abdominal cavity. Patient selection is rigorous — not every patient with peritoneal disease is suitable.
The most common indication for HIPEC. Peritoneal spread from colorectal cancer previously meant median survival of 6–12 months with chemotherapy. CRS + HIPEC with Oxaliplatin can achieve median survival of 40–63 months in selected patients (PCI ≤ 15, CC0/CC1).
Interval CRS + HIPEC after neoadjuvant chemotherapy, or second-look HIPEC for recurrent platinum-sensitive ovarian cancer. HIPEC with Cisplatin improves overall survival compared to surgery alone in stage III ovarian cancer (OVHIPEC trial — N Engl J Med 2018).
A rare condition of mucinous tumour arising from the appendix, spreading mucinous deposits throughout the peritoneum. Without surgery, PMP is universally fatal. With CRS + HIPEC, 10-year survival exceeds 60–70% and disease-free survival approaches 90% at 5 years in low-grade PMP — approaching curative in expert centres.
Peritoneal metastases from gastric cancer carry a very poor prognosis. In highly selected patients with synchronous limited peritoneal spread (PCI ≤ 6) and good response to neoadjuvant chemotherapy, CRS + HIPEC with Cisplatin or Docetaxel may offer survival benefit over chemotherapy alone.
A rare malignancy arising from the peritoneum itself — distinct from pleural mesothelioma. CRS + HIPEC with Cisplatin + Doxorubicin is the treatment of choice for resectable peritoneal mesothelioma — achieving median survival of 40–92 months compared to <12 months with chemotherapy alone.
Prophylactic HIPEC at the time of surgery for T4 colorectal cancer or perforated colorectal cancer (high peritoneal seeding risk) is under clinical investigation. HIPEC is also performed for selected appendiceal cancers (excluding low-grade PMP), and occasionally other peritoneal surface malignancies.
The Peritoneal Cancer Index (PCI) is the most important tool in CRS + HIPEC planning. It scores the distribution and size of peritoneal tumour deposits across 13 abdominal and pelvic regions, on a scale of 0–39.
Each region is scored 0 (no tumour) to 3 (tumour > 5cm or confluent deposits). The total PCI score determines operability and predicts outcome. A PCI of 0 means no peritoneal disease. A PCI of 39 means every region has large, confluent tumour deposits — not suitable for curative surgery.
PCI is assessed on pre-operative PET-CT and MRI, and confirmed intraoperatively. The decision to proceed or abandon is sometimes made on the operating table — based on actual PCI findings.
Drug selection for HIPEC is based on the cancer type, prior chemotherapy exposure, and surgeon/centre preference. All agents are given at therapeutic concentrations in heated carrier solution.
| Drug | Cancer Indication | Temperature | Duration | Why This Drug |
|---|---|---|---|---|
| Oxaliplatin | ColorectalAppendiceal | 42–43°C | 30–60 min | Platinum drug — DNA cross-linking; heat significantly enhances cytotoxicity; shorter duration due to high temperature. Given with systemic 5-FU. |
| Cisplatin | OvarianMesotheliomaGastric | 41–42°C | 60–90 min | Standard platinum agent; excellent peritoneal penetration; heat enhances uptake and cytotoxicity. OVHIPEC trial: level 1 evidence in ovarian cancer. |
| Mitomycin C (MMC) | ColorectalPMPAppendiceal | 41–42°C | 90 min | Alkylating agent — cross-links DNA and inhibits replication. Long track record in HIPEC; effective against mucinous tumours including PMP. |
| Doxorubicin | MesotheliomaSarcoma | 41–42°C | 90 min | Anthracycline — intercalates DNA and inhibits topoisomerase II. Often combined with Cisplatin for peritoneal mesothelioma. Heat increases uptake. |
| Docetaxel | GastricOvarian | 41°C | 60 min | Taxane — stabilises microtubules and prevents cell division. Used in gastric HIPEC, particularly in Asian protocols. Heat enhances cellular uptake. |
| 5-Fluorouracil (5-FU) | ColorectalGastric | 41°C | 90 min | Antimetabolite — often used as early postoperative intraperitoneal chemotherapy (EPIC) following CRS, complementing intraoperative HIPEC with MMC or Oxaliplatin. |
CRS + HIPEC has moved from an experimental procedure to the standard of care for selected peritoneal malignancies — supported by randomised controlled trials, prospective registries, and over 30 years of surgical experience at specialised centres.
Rigorous patient selection is the foundation of good HIPEC outcomes. Operating on unsuitable patients risks major morbidity without meaningful survival benefit.
CRS + HIPEC is one of the most major operations in surgical oncology. Honest counselling about risk is essential. Morbidity is significant — but in the right patient, the survival benefit justifies it.
Major peritonectomy involves significant blood loss. Blood transfusion is commonly required. Cell salvage techniques are used where possible.
Multiple bowel resections increase leak risk (5–10%). Anastomotic leak after HIPEC may be more serious than standard surgery — often requires re-operation and stoma.
Prolonged surgery, bowel handling, and immunosuppressive effects of chemotherapy increase infection risk — wound, intra-abdominal, and respiratory infections.
Systemic absorption of heated chemotherapy can suppress bone marrow — causing leucopenia, thrombocytopenia. Monitored with regular blood counts post-operatively.
In experienced centres performing >20 CRS + HIPEC cases per year, operative mortality is <3%. Risk increases with high PCI, multiple organ resections, and patient comorbidity.
Post-operative monitoring in ICU — fluid balance, haemodynamic stability, organ function. Nasogastric tube and urinary catheter in situ. Early physiotherapy begins.
Transfer to surgical ward as condition stabilises. Gradual introduction of fluids and diet. Drain management. Daily blood count monitoring for chemotherapy toxicity.
Patients who have an uncomplicated course are typically discharged at 10–14 days. Drain removed, wounds healing, tolerating a soft diet.
Return to full activity, including light work. Systemic adjuvant chemotherapy may begin after 4–6 weeks. First follow-up CT or PET-CT at 3 months post-operatively.
Regular CT / PET-CT surveillance every 3–6 months for 2 years, then annually. Tumour markers (CEA, CA-125) monitored at each visit. Recurrence in the peritoneum may be re-resectable.
If you or your patient has peritoneal metastases from colorectal cancer, ovarian cancer, PMP, or mesothelioma — book a specialist HIPEC assessment with Dr. Gore. PCI evaluation, resectability assessment, and a complete treatment plan will be provided.